FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037877162> ?p ?o ?g. }

• W3037877162 endingPage "e000928" @default.
• W3037877162 startingPage "e000928" @default.
• W3037877162 abstract "Background Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity. Methods In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early-stage PCa and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T-cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate-specific antigen (PSA) change, and assessment of phenotype and functionality of antigen-specific T cells. Results The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T-cell responses were measured in blood by ex vivo IFN-γ ELISpot and were detected in the majority of patients with a mean level in responders of 198 spot-forming cells per million peripheral blood mononuclear cells. Flow cytometry analysis demonstrated the presence of both CD8+ and CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumor-infiltrating lymphocytes were isolated from post-treatment prostate tissue. Some of the patients had a transient PSA rise 2–8 weeks following vaccination, possibly indicating an inflammatory response in the target organ. Conclusions An excellent safety profile and T-cell responses elicited in the circulation and also detected in the prostate gland support the evaluation of the ChAdOx1-MVA 5T4 vaccine in efficacy trials. It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab. Trial registration The trial was registered with the U.S. National Institutes of Health (NIH) Clinical Trials Registry (ClinicalTrials.gov identifier NCT02390063 )." @default.
• W3037877162 created "2020-07-02" @default.
• W3037877162 creator A5000092650 @default.
• W3037877162 creator A5004102058 @default.
• W3037877162 creator A5005073157 @default.
• W3037877162 creator A5006757599 @default.
• W3037877162 creator A5012694886 @default.
• W3037877162 creator A5012821937 @default.
• W3037877162 creator A5019032517 @default.
• W3037877162 creator A5022333191 @default.
• W3037877162 creator A5029624551 @default.
• W3037877162 creator A5032231578 @default.
• W3037877162 creator A5037138357 @default.
• W3037877162 creator A5040192632 @default.
• W3037877162 creator A5040896653 @default.
• W3037877162 creator A5057465231 @default.
• W3037877162 creator A5062742458 @default.
• W3037877162 creator A5062938315 @default.
• W3037877162 creator A5065386559 @default.
• W3037877162 creator A5066415190 @default.
• W3037877162 creator A5071335044 @default.
• W3037877162 creator A5072889147 @default.
• W3037877162 creator A5080403954 @default.
• W3037877162 creator A5085075211 @default.
• W3037877162 creator A5090096123 @default.
• W3037877162 creator A5091543009 @default.
• W3037877162 date "2020-06-01" @default.
• W3037877162 modified "2023-10-18" @default.
• W3037877162 title "Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial" @default.
• W3037877162 cites W1572810235 @default.
• W3037877162 cites W1833523230 @default.
• W3037877162 cites W1970569268 @default.
• W3037877162 cites W1983356813 @default.
• W3037877162 cites W1991737813 @default.
• W3037877162 cites W2003782011 @default.
• W3037877162 cites W2015466920 @default.
• W3037877162 cites W2022493258 @default.
• W3037877162 cites W2033938517 @default.
• W3037877162 cites W2036481615 @default.
• W3037877162 cites W2037474484 @default.
• W3037877162 cites W2038281342 @default.
• W3037877162 cites W2046731610 @default.
• W3037877162 cites W2053396704 @default.
• W3037877162 cites W2063937996 @default.
• W3037877162 cites W2067809413 @default.
• W3037877162 cites W2071124717 @default.
• W3037877162 cites W2071708298 @default.
• W3037877162 cites W2076682071 @default.
• W3037877162 cites W2095135796 @default.
• W3037877162 cites W2103959341 @default.
• W3037877162 cites W2121290865 @default.
• W3037877162 cites W2154495308 @default.
• W3037877162 cites W2156965423 @default.
• W3037877162 cites W2170056895 @default.
• W3037877162 cites W2312123827 @default.
• W3037877162 cites W2328562440 @default.
• W3037877162 cites W2343314930 @default.
• W3037877162 cites W2466485619 @default.
• W3037877162 cites W2612201011 @default.
• W3037877162 cites W2753140990 @default.
• W3037877162 cites W2790577051 @default.
• W3037877162 cites W2804294118 @default.
• W3037877162 cites W2805721567 @default.
• W3037877162 cites W2896846797 @default.
• W3037877162 cites W2903311535 @default.
• W3037877162 cites W2903991686 @default.
• W3037877162 cites W2915177933 @default.
• W3037877162 cites W2971546771 @default.
• W3037877162 cites W3015726774 @default.
• W3037877162 cites W3101564865 @default.
• W3037877162 doi "https://doi.org/10.1136/jitc-2020-000928" @default.
• W3037877162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7319775" @default.
• W3037877162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32591433" @default.
• W3037877162 hasPublicationYear "2020" @default.
• W3037877162 type Work @default.
• W3037877162 sameAs 3037877162 @default.
• W3037877162 citedByCount "24" @default.
• W3037877162 countsByYear W30378771622021 @default.
• W3037877162 countsByYear W30378771622022 @default.
• W3037877162 countsByYear W30378771622023 @default.
• W3037877162 crossrefType "journal-article" @default.
• W3037877162 hasAuthorship W3037877162A5000092650 @default.
• W3037877162 hasAuthorship W3037877162A5004102058 @default.
• W3037877162 hasAuthorship W3037877162A5005073157 @default.
• W3037877162 hasAuthorship W3037877162A5006757599 @default.
• W3037877162 hasAuthorship W3037877162A5012694886 @default.
• W3037877162 hasAuthorship W3037877162A5012821937 @default.
• W3037877162 hasAuthorship W3037877162A5019032517 @default.
• W3037877162 hasAuthorship W3037877162A5022333191 @default.
• W3037877162 hasAuthorship W3037877162A5029624551 @default.
• W3037877162 hasAuthorship W3037877162A5032231578 @default.
• W3037877162 hasAuthorship W3037877162A5037138357 @default.
• W3037877162 hasAuthorship W3037877162A5040192632 @default.
• W3037877162 hasAuthorship W3037877162A5040896653 @default.
• W3037877162 hasAuthorship W3037877162A5057465231 @default.
• W3037877162 hasAuthorship W3037877162A5062742458 @default.
• W3037877162 hasAuthorship W3037877162A5062938315 @default.
• W3037877162 hasAuthorship W3037877162A5065386559 @default.

• next